
Please try another search
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Name | Age | Since | Title |
---|---|---|---|
Edward J. Borkowski | 67 | 2015 | Lead Independent Director |
Manpreet Uppal | 38 | 2025 | Independent Director |
Richard Joel Paolone | 35 | 2025 | Interim CEO & Chairman |
Jack A. Syage | 70 | 2024 | Director |
Eric G. Corbett | 29 | 2025 | Independent Director |
Geordan G. Pursglove | 37 | 2025 | Director |
Jason D. Sawyer | 32 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review